MCID: PDT040
MIFTS: 27

Pediatric Hypertension

Categories: Rare diseases

Aliases & Classifications for Pediatric Hypertension

MalaCards integrated aliases for Pediatric Hypertension:

Name: Pediatric Hypertension 53

Classifications:



Summaries for Pediatric Hypertension

MalaCards based summary : Pediatric Hypertension is related to aortic coarctation and malignant hypertension. An important gene associated with Pediatric Hypertension is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Peptide hormone metabolism and Renin secretion. The drugs Lisinopril and Amlodipine have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and testes.

Related Diseases for Pediatric Hypertension

Diseases related to Pediatric Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Related Disease Score Top Affiliating Genes
1 aortic coarctation 29.7 AGT ACE
2 malignant hypertension 29.3 AGT ACE
3 fibromuscular dysplasia 29.3 AGT ACE
4 hypertension, essential 29.1 AGT ADD1 ACE
5 end stage renal failure 28.9 AGT ACE
6 kidney disease 10.0 AGT ACE
7 renal artery disease 10.0 AGT ACE
8 posterior urethral valves 10.0 AGT ACE
9 anuria 10.0 AGT ACE
10 microvascular complications of diabetes 3 9.9 AGT ACE
11 diastolic heart failure 9.9 AGT ACE
12 renal tubular dysgenesis 9.9 AGT ACE
13 hypertensive heart disease 9.9 AGT ACE
14 interstitial nephritis 9.9 AGT ACE
15 mitral valve disease 9.8 AGT ACE
16 obstructive nephropathy 9.8 AGT ACE
17 renovascular hypertension 9.8
18 oligohydramnios 9.8 AGT ACE
19 meningococcal infection 9.8 AGT ADD1
20 renal dysplasia 9.8 AGT ACE
21 vesicoureteral reflux 1 9.7
22 body mass index quantitative trait locus 1 9.7
23 aortic valve disease 2 9.7 AGT ACE
24 hyperaldosteronism, familial, type i 9.6
25 congenital anomalies of kidney and urinary tract 2 9.6
26 hutchinson-gilford progeria syndrome 9.6
27 apparent mineralocorticoid excess 9.6
28 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.6
29 aging 9.6
30 renal hypertension 9.6
31 chronic pyelonephritis 9.6
32 hydrocephalus 9.6
33 pyelonephritis 9.6
34 hypertensive retinopathy 9.6
35 hyperuricemia 9.6
36 arteriosclerosis 9.6
37 glomerulonephritis 9.6
38 thrombophlebitis 9.6
39 placental insufficiency 9.6
40 uremia 9.6
41 arteriolosclerosis 9.6
42 ureteral obstruction 9.6
43 cerebrovascular disease 9.6
44 chronic kidney disease 9.6
45 intracranial hypertension 9.6
46 renal tuberculosis 9.6
47 47,xyy 9.6
48 congenital hydrocephalus 9.6
49 familial hypertension 9.6
50 aneurysm 9.6

Graphical network of the top 20 diseases related to Pediatric Hypertension:



Diseases related to Pediatric Hypertension

Symptoms & Phenotypes for Pediatric Hypertension

Drugs & Therapeutics for Pediatric Hypertension

DrugBank drugs 16 :

# Drug Name Indication DrugBank ID
1 Valsartan **Monotherapy** Valsartan may be used alone for the management of hypertension [FDA label] **Combination therapy** Valsartan is indicated for the management of hypertension in patients for whom combination therapy is deemed appropriate [F3139]. It is combined with other anthypertensive agents such as hydrochlorothiazide, amlodipine, nevibolol and sacubitril [F3139], [F3136], [F3145], [F3148]. **Heart Failure** Valsartan is indicated for the treatment of heart failure (NYHA class II-IV) in patients who are intolerant to angiotensin-converting enzyme inhibitors (ACE inhibitors) for various reasons, including those who experience ACE inhibitor adverse effects. In a clinical study of 5010 patients, hospitalizations due to heart failure were markedly decreased when valsartan was taken regularly over a 2-year span [FDA label]. DB00177

Drugs for Pediatric Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
2
Amlodipine Approved Phase 4 88150-42-9 2162
3
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
4 Sodium Chloride Symporter Inhibitors Phase 4
5 Cardiotonic Agents Phase 4
6 Natriuretic Agents Phase 4
7 HIV Protease Inhibitors Phase 4
8 diuretics Phase 4
9
protease inhibitors Phase 4
10 Protective Agents Phase 4
11 Angiotensin-Converting Enzyme Inhibitors Phase 4
12
Valsartan Approved, Investigational Phase 3 137862-53-4 60846
13
Metoprolol Approved, Investigational Phase 3 37350-58-6, 51384-51-1 4171
14
Candesartan cilexetil Approved Phase 3 145040-37-5 2540
15
Enalapril Approved, Vet_approved Phase 3 75847-73-3 5362032 40466924
16
Enalaprilat Approved Phase 3 76420-72-9 6917719
17
Angiotensin II Approved, Investigational Phase 3 11128-99-7, 68521-88-0, 4474-91-3 172198
18
Losartan Approved Phase 3 114798-26-4 3961
19
Azilsartan medoxomil Approved, Investigational Phase 3 863031-21-4
20
Sodium citrate Approved, Investigational Phase 3 68-04-2
21
Bosentan Approved, Investigational Phase 3 147536-97-8 104865
22
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
23
Candesartan Experimental Phase 3 139481-59-7 2541
24 Pharmaceutical Solutions Phase 3
25 Neurotransmitter Agents Phase 3
26 Adrenergic beta-1 Receptor Antagonists Phase 3
27 Adrenergic beta-Antagonists Phase 3
28 Adrenergic Antagonists Phase 3
29 Peripheral Nervous System Agents Phase 3
30 Sympatholytics Phase 3
31 Adrenergic Agents Phase 3
32 Autonomic Agents Phase 3
33 Angiotensinogen Phase 3
34 Angiotensin II Type 1 Receptor Blockers Phase 3
35 Angiotensin Receptor Antagonists Phase 3
36 Giapreza Phase 3
37 Anti-Arrhythmia Agents Phase 3
38 Antihypertensive Agents Phase 3
39 Vasodilator Agents Phase 3
40 Sildenafil Citrate Phase 3 171599-83-0
41 Citrate Phase 3
42 Phosphodiesterase Inhibitors Phase 3
43 Phosphodiesterase 5 Inhibitors Phase 3
44 Endothelin Receptor Antagonists Phase 3
45
Probenecid Approved, Investigational Phase 2 57-66-9 4911
46
Allopurinol Approved Phase 2 315-30-0 2094
47 Antioxidants Phase 2
48 Renal Agents Phase 2
49 Free Radical Scavengers Phase 2
50 Antimetabolites Phase 2

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 A Randomized Clinical Trial of the N-of-1 Approach in Children With Hypertension Recruiting NCT03461003 Phase 4 Amlodipine;Lisinopril;Hydrochlorothiazide;Losartan
2 A Double-Blind, Randomized, Multi-Center Study Followed By 12 Months Open-Label Treatment To Evaluate The Dose Response And Safety Of Valsartan In Pediatric Hypertension Patients 1 - 5 Years Of Age Completed NCT00171028 Phase 3 valsartan
3 A Double-Blind, Randomized, Multi-Center Study Followed By 12 Months Open-Label Treatment To Evaluate The Dose Response And Safety Of Valsartan In Pediatric Hypertensive Patients Completed NCT00171041 Phase 3 valsartan
4 A 6 Week, Randomized, Multicenter, Double-blind, Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension, With or Without Chronic Kidney Disease, Followed by a 20 Week Open-label Titration Phase Completed NCT01617681 Phase 3 VAL489;VAL489 matching placebo
5 A Multicenter, Open-label, 18 Month Study to Evaluate the Long-term Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age With Hypertension and With or Without Chronic Kidney Disease Completed NCT01365481 Phase 3 Valsartan;amlodipine;Hydrochlorothiazide
6 Dose Ranging, Safety and Tolerability of TOPROL-XL® (Metoprolol Succinate) Extended-Release Tablets (Metoprolol CR/XL) in Hypertensive Pediatric Subjects: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Completed NCT00255528 Phase 3 metoprolol succinate
7 A Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® (Metoprolol Succinate) Extended-Release Tablets (Metoprolol CR/XL) in Hypertensive Pediatric Subjects: A Multicenter, Open-Label Extension of Protocol 307A Completed NCT00255502 Phase 3 metoprolol succinate
8 A Dose-Ranging and Safety Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 6 to <17 Years of Age: A 4-Week, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Completed NCT00244634 Phase 3 candsartan cilexetil
9 A Dose-ranging Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less That 6 Years of Age: A 4-week, Multicenter, Randomized, Double-blind Study With a 1-year, Open-label, Follow-up Period. Completed NCT00244621 Phase 3 candesartan cilexetil (Atacand);candesartan cilexetil (Atacand);candesartan cilexetil (Atacand)
10 A Multicenter, Multinational, Open-Label Study of the Efficacy, Safety, and Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age Completed NCT00244595 Phase 3 candsartan cilexetil
11 An Open-label, Phase 3, Multicenter Study to Evaluate the Pharmacokinetics Following a Single Oral Dose of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension Completed NCT02451150 Phase 3 Azilsartan
12 A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety, Efficacy and Pharmacokinetics of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension Completed NCT02791438 Phase 3 TAK-536 2.5 mg;TAK-536 5 mg
13 A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age Completed NCT01151410 Phase 3 Aliskiren;Enalapril
14 A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age Completed NCT01150357 Phase 3 Aliskiren (6.25/12.5/25 mg);Aliskiren (37.5/75/150 mg);Aliskiren (150/300/600 mg)
15 The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution After the Bidirectional Cavopulmonary Connection Completed NCT00741156 Phase 3 Enalaprilat
16 A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension Active, not recruiting NCT02235909 Phase 3 Azilsartan Medoxomil;Losartan;Placebo for Azilsartan Medoxomil;Placebo for Losartan
17 Kids MoD PAH Trial: Mono- vs. Duo-Therapy for Pediatric Pulmonary Arterial Hypertension Not yet recruiting NCT04039464 Phase 3 Mono-Therapy with Sildenafil;Duo-Therapy with Sildenafil + Bosentan
18 An 8-day Open-label, Multiple-dose, Multicenter Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age Completed NCT00834041 Phase 1, Phase 2 Aliskiren 3.125 mini-tablets
19 Primary Prevention of Hypertension in Obese Adolescents Completed NCT00288158 Phase 2 Allopurinol;Probenecid;Placebo
20 Chronobiology and Chronopharmacology to Prevent Sickle Cell Kidney Disease Recruiting NCT02373241 Phase 2 Losartan;Losartan
21 A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension Withdrawn NCT00528827 Phase 2 Cardene® I.V.
22 A Multicenter, Double-blind 52 to 104 Week Off-therapy Extension Study to Evaluate the Long Term Growth and Development of Pediatric Hypertensive Patients 6 - 17 Years of Age Previously Treated With Aliskiren in Studies CSPP100A2365 and/or CSPP100A2365E1 Completed NCT01420068 SPP100
23 Improving Outcomes for Hypertensive Children Completed NCT01485783
24 Statistical Analysis of Pediatric Task Force Data Base Completed NCT00005407
25 Pediatric Hypertension Registry (PHREG) Enrolling by invitation NCT03305562
26 BP-CATCH: Boosting Primary Care Awareness and Treatment of Childhood Hypertension Enrolling by invitation NCT03783650

Search NIH Clinical Center for Pediatric Hypertension

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Valsartan

Genetic Tests for Pediatric Hypertension

Anatomical Context for Pediatric Hypertension

MalaCards organs/tissues related to Pediatric Hypertension:

41
Kidney, Heart, Testes, Bone, Brain, Bone Marrow

Publications for Pediatric Hypertension

Articles related to Pediatric Hypertension:

(show top 50) (show all 254)
# Title Authors PMID Year
1
Hemorrhagic stroke and renovascular hypertension with Grange syndrome arising from a novel pathogenic variant in YY1AP1. 38
31270375 2019
2
Pediatric Hypertension: Review of Updated Guidelines. 38
31263043 2019
3
Screening for pediatric hypertension: How many readings are enough? 38
31359598 2019
4
Ambulatory Blood Pressure Monitoring in Pediatrics. 38
31350605 2019
5
2017 Pediatric Hypertension Guidelines Improve Prediction of Adult Cardiovascular Outcomes. 38
31006329 2019
6
Research Gaps in Primary Pediatric Hypertension. 38
31023830 2019
7
The cardiovascular phenotype of childhood hypertension: a cardiac magnetic resonance study. 38
31053874 2019
8
Predictors and Consequences of Pediatric Hypertension: Have Advanced Echocardiography and Vascular Testing Arrived? 38
31134437 2019
9
Impact of updated pediatric hypertension guidelines on progression from elevated blood pressure to hypertension in a community-based primary care population. 38
30980615 2019
10
Treating Hypertension in Children With n-of-1 Trials. 38
30842257 2019
11
Coarctation of the Aorta in Adolescence: Significance of Detailed Cardiac Examination in Pediatric Hypertension. 38
30973498 2019
12
Pediatric hypertension: Cardiovascular prevention must begin early in life. 38
31029492 2019
13
Blood Pressure Trajectories from Childhood to Adolescence in Pediatric Hypertension. 38
30808073 2019
14
High blood pressure in schoolchildren: Associated sociodemographic and biochemical factors. 38
31005363 2019
15
Pediatric hypertension and hypertensive emergencies: recognition and management in the emergency department. 38
30794368 2019
16
Points & Pearls: Pediatric hypertension and hypertensive emergencies: recognition and management in the emergency department 38
30821950 2019
17
Methodological and reporting quality of systematic reviews referenced in the clinical practice guideline for pediatric high-blood pressure. 38
30045363 2019
18
Updates to pediatric hypertension guidelines: influence on classification of high blood pressure in children and adolescents. 38
30044314 2019
19
Systematic reviews: a small fraction of the evidence used to generate the 2017 clinical pediatric hypertension clinical practice guideline. 38
30640876 2019
20
Pediatric Hypertension: Diagnosis, Evaluation, and Treatment. 38
30454750 2019
21
Clinical, Biochemical, and Genetic Characteristics of "Nonclassic" Apparent Mineralocorticoid Excess Syndrome. 38
30239803 2019
22
Unilateral renal artery stenosis presented with hyponatremic-hypertensive syndrome - case report and literature review. 38
30791890 2019
23
The Evaluation of a 19-Year-Old With Hypertension and Proteinuria: A Case Report. 38
31064291 2019
24
Prevalence of Hypertension in Children. 38
30571555 2019
25
Epidemiology of Childhood Onset Essential Hypertension. 38
30224771 2018
26
Pediatric Hypertension. 38
30543379 2018
27
Target Organ Abnormalities in Pediatric Hypertension. 38
30122368 2018
28
Familial aggregation of first degree relatives of children with essential hypertension. 38
29699426 2018
29
Surveillance of Pediatric Hypertension Using Smartphone Technology. 38
30005962 2018
30
Pediatric hypertension: diagnostic patterns derived from electronic health records. 38
30130249 2018
31
Home blood pressure monitoring in pediatric hypertension: the US perspective and a plan for action. 38
30054592 2018
32
Importance of ambulatory blood pressure monitoring in the diagnosis and prognosis of pediatric hypertension. 38
29871785 2018
33
Pharmacological Treatment of Arterial Hypertension in Children and Adolescents: A Network Meta-Analysis. 38
29967035 2018
34
Clinical Implications of the Revised AAP Pediatric Hypertension Guidelines. 38
29976572 2018
35
[17α-Hydroxylase deficiency with severe hypertension as the initial symptom in a child]. 38
30111479 2018
36
Hypertension Among Youths - United States, 2001-2016. 38
30001558 2018
37
Utility of Doppler sonography for renal artery stenosis screening in obese children with hypertension. 38
29575497 2018
38
An Update on Hypertension in Children With Type 1 Diabetes. 38
29602408 2018
39
Pediatric renovascular hypertension: Treatment outcome according to underlying disease. 38
29281158 2018
40
Varying blood pressure in children: a diagnostic quandary interpreting the Fourth Report. 38
29459220 2018
41
Cardiac and Vascular Target Organ Damage in Pediatric Hypertension. 38
29881718 2018
42
Editorial: Pediatric Hypertension: Update. 38
30109219 2018
43
Adverse Outcomes in Pediatric Hypertension. 38
29084875 2017
44
Changes in the 2017 Pediatric Hypertension Clinical Guidelines. 38
29087430 2017
45
Ambulatory Blood Pressure Monitoring in Children and Adolescents: a Review of Recent Literature and New Guidelines. 38
29071489 2017
46
Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. 38
28827377 2017
47
Primary Pediatric Hypertension: Current Understanding and Emerging Concepts. 38
28780627 2017
48
Ultrasound imaging of renin-mediated hypertension. 38
28779201 2017
49
Looking for new diagnostic tools and biomarkers of hypertension in obese pediatric patients. 38
28272108 2017
50
Prevalence of high blood pressure subtypes and its associations with BMI in Chinese children: a national cross-sectional survey. 38
28651555 2017

Variations for Pediatric Hypertension

Expression for Pediatric Hypertension

Search GEO for disease gene expression data for Pediatric Hypertension.

Pathways for Pediatric Hypertension

Pathways related to Pediatric Hypertension according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.22 AGT ACE
2 10.46 AGT ACE

GO Terms for Pediatric Hypertension

Biological processes related to Pediatric Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 9.46 AGT ACE
2 positive regulation of protein binding GO:0032092 9.43 ADD1 ACE
3 regulation of blood pressure GO:0008217 9.4 AGT ACE
4 positive regulation of protein tyrosine kinase activity GO:0061098 9.37 AGT ACE
5 blood vessel remodeling GO:0001974 9.32 AGT ACE
6 regulation of vasoconstriction GO:0019229 9.26 AGT ACE
7 positive regulation of blood pressure GO:0045777 9.16 AGT ACE
8 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 8.96 AGT ACE
9 regulation of renal output by angiotensin GO:0002019 8.62 AGT ACE

Sources for Pediatric Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....